HOME ·

01177.HK

SBP GROUP (01177.HK): TQC2731 Phase III fully enrolled in CRSwNP
Tags：
SBP GROUP01177.HKR&D Progress
2026-10-21
SBP GROUP (01177.HK): TQ-A3334, Bepirovirsen Data Picked for AASLD
Tags：
SBP GROUP01177.HKR&D Progress
2026-10-14
SBP GROUP (01177.HK): TQC3721 Phase III completes enrolment
Tags：
SBP GROUP01177.HKR&D Progress
2026-10-08
SBP GROUP (01177.HK): NDA for TQH2722 "IL-4Rα Antibody" Accepted for Review
Tags：
NewTimeSpaceSBP GROUP01177.HK
2026-09-16
SBP GROUP (01177.HK): NDA for TQB2102 "HER2 Bispecific ADC" Accepted for Review
Tags：
NewTimeSpaceSBP GROUP01177.HK
2026-09-16
SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-08
SBP GROUP (01177.HK): Phase I data of TQC3721 dry powder inhaler (PDE3/4 inhibitor) presented at ERS 2026, showing dose-dependent lung function improvement in COPD
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-07
SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors
Tags：
SBP GROUP01177.HKR&D Progress
2026-09-03
SBP GROUP (01177.HK): Enters Exclusive Licensing Agreement with Cipla for TQB2102, with Deal Value Up to USD 123 Million
Tags：
SBP GROUP01177.HKstrategic cooperation
2026-08-31
SBP GROUP (01177.HK): Kylo-11 Phase I data published in The Lancet; single dose reduces Lp(a) by up to 97% at week 48
Tags：
SBP GROUP01177.HKClinical Progress
2026-08-31
SBP GROUP (01177.HK): LM-364 "Nectin-4ᵀᴹᴱ ADC" Obtains Clinical Trial Approvals from NMPA and FDA, Accelerating Global Clinical Development
Tags：
SBP GROUP01177.HKClinical Trial
2026-08-28
SBP GROUP (01177.HK): New Indication of Benmelstobart plus Chemotherapy Sequentially with Anlotinib as First-Line Treatment for Squamous NSCLC Approved for Marketing
Tags：
SBP GROUP01177.HKR&D Progress
2026-08-07
Sino Biopharmaceutical (01177.HK): Second-Generation Flurbiprofen Patch Approved for Marketing
Tags：
Sino Biopharmaceutical01177.HK
2026-08-06
SBP GROUP(01177.HK): NDA for BCL‑2 Inhibitor TQB3909 Accepted, for Treatment of CLL/SLL
Tags：
SBP GROUP01177.HKNew Drug Application
2026-08-04
SBP GROUP(01177.HK): HER2 Bispecific ADC TQB2102 Receives Third CDE Breakthrough Therapy Designation for HER2-Low
Tags：
SBP GROUP01177.HKbreakthrough drug
2026-08-03
SBP GROUP (01177.HK): Establishes Joint Venture with Indonesia’s Tempo Scan Holding 51% Stake to Expand Innovative Drug Market in Southeast Asia
Tags：
SBP GROUP01177.HKjoint venture company
2026-07-27
SBP GROUP (01177.HK): IM-101 Injection (PreS1 Recombinant Fusion Protein) Obtains NMPA Clinical Trial Approval for Chronic Hepatitis B
Tags：
SBP GROUP01177.HKClinical Trial
2026-07-23
Sino Biopharmaceutical (01177.HK): TRD205 (AT2R Antagonist) Included in CDE’s Breakthrough Therapy Designation List
Tags：
Sino Biopharmaceutical01177.HK
2026-07-14
SBP GROUP (01177.HK): NDA Accepted for Category 1 Innovative Drug IDH1 Inhibitor TQB3454 for Advanced Biliary Tract Cancer
Tags：
SBP GROUP01177.HKNew Drug Application
2026-07-10
SINO BIOPHARM(01177.HK): Deepens Exclusive Strategic Cooperation with GSK, Secures Commercialisation Rights for Two Core Innovative Respiratory Drugs
Tags：
SINO BIOPHARM01177.HKGSKcooperation
2026-07-08
12